Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Salbutamol + bromhexine + menthol is a fixed-dose combination (FDC) medication primarily used to treat respiratory conditions characterized by bronchospasm and excessive, viscous mucus. Salbutamol is a short-acting beta-2 adrenergic receptor agonist that promotes bronchodilation by increasing intracellular cAMP levels, which leads to the relaxation of bronchial smooth muscle. Bromhexine acts as a mucolytic and secretolytic agent; it increases the production of serous mucus in the respiratory tract and facilitates the breakdown of acid mucopolysaccharide fibers in thick phlegm, making it less viscous and easier to expectorate. Menthol is included for its cooling and soothing properties, which are mediated through the activation of TRPM8 receptors in the upper respiratory tract, providing relief from throat irritation and a mild antitussive effect. This combination is commonly prescribed as an oral syrup for patients suffering from productive cough associated with asthma, bronchitis, or chronic obstructive pulmonary disease (COPD).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on salbutamol + bromhexine + menthol.